Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
J. Clin. Invest. Elena Quaglino, et al. 113:709 doi:10.1172/JCI19850 [Go to this article.]

Figure 1
Effects of TM-ECD vaccination and p185^neu/allo^q-IFNγ cells boost on the progression of precancerous lesions in BALB-neuT mice. (A–C) Whole-mount analysis of mammary glands. The nipple areas are indicated by the arrows. Magnification, ×6.3. (A) Wk10nt mammary glands show several atypical hyperplasia foci forming multiple ductal side buds, sometimes coalescing in larger nodules representing in situ carcinomas. (B) Wk22nt mammary glands; a large portion is occupied by nodular masses corresponding to invasive carcinomas. (C) Wk22pb mammary glands. (D) Percentage of tumor-free mice and (E) tumor multiplicity in BALB-neuT mice. TM-ECD–vaccinated mice (open squares, 18 mice); p185^neu/allo^q-IFNγ cell–vaccinated mice (open circles, 5 mice); primed-and-boosted mice (filled squares, 21 mice); and primed-and-boosted BALB-neuT/μKO mice (filled triangles, 5 mice). Tumor-free survival curve of primed-and-boosted BALB-neuT mice is significantly different (Mantel-Haenszel test) from that of TM-ECD–vaccinated BALB-neuT mice (P < 0.0001) and that of primed-and-boosted BALB-neuT/μKO mice (P < 0.009). From week 23, the mean tumor multiplicity in primed-and-boosted BALB-neuT mice is significantly different from that of TM-ECD–vaccinated mice (P = 0.0002, Student’s t test). Vertical bars represent SE. This experiment was repeated three times. The cumulative data are shown.